Compare Fastly Inc (FSLY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Novartis AG — how do they compare? Fastly Inc trades at $26.89 (market cap $4.03B), while Novartis AG trades at $143.34 (market cap $268.57B). The key difference: Novartis AG is far larger — about 66.6× Fastly Inc's market cap, and Novartis AG pays a 3.31% dividend while Fastly Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Novartis AG for 82 Days on average.
| FSLY | NVS | |
|---|---|---|
Market Cap | $4.03B | $268.57B |
Volume | 5,516,495 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $33.50 | $168.62 |
52-Week Low | $7.86 | $121.80 |
Typical Hold Time | 26 Days | 82 Days |
Enterprise Value | $4.09B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $25.28, down 0.9% on the day, amid mixed technical and fundamental signals. The stock exhibits a bullish technical trend with support near $25, while recent earnings have consistently beaten expectations. Revenue growth is robust, projected to reach $687 million in 2026, but profitability remains elusive with a net income margin of -11.8%. The company's strategic focus on AI and edge cloud infrastructure, highlighted during its recent Investor Day, fuels optimism for long-term growth.
The investment outlook for FSLY balances strong revenue expansion and AI-driven opportunities against persistent losses and insider selling. While analyst consensus leans neutral with a $28.25 price target, the stock's valuation appears stretched relative to earnings. Key risks include competitive pressures in edge computing and the need to translate top-line growth into sustainable profitability. Investors should weigh the company's growth trajectory against its current financial health.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
